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Abstract
Background: There is increasing evidence that the non-neuronal cholinergic system might be of importance for
the pathology of rheumatoid arthritis. The role of M3 muscarinic acetylcholine receptor (M3R) in this regard has,
however, not been investigated to date. Thus, in the present study we analyzed if M3R deficiency might have a
protective effect on experimentally induced arthritis.
Methods: Collagen antibody-induced arthritis (CAIA) was evoked in M3R-deficient (M3R−/−) mice and wild-type
(WT) littermates. Severity of arthritis was assessed by scoring of paw swelling. The joints of arthritic and nonarthritic
animals were analyzed for histopathological changes regarding synovial tissue, cartilage degradation and bone
destruction. Further, gene expression analysis of respective markers was performed. Systemic and local inflammatory
response was determined by flow cytometry and immunohistochemistry for leukocytes as well as mRNA and protein
measurements for pro-inflammatory cytokines and chemokines.
Results: In arthritic M3R−/− mice the number of leukocytes, specifically neutrophils, was enhanced even though clinical
arthritis score was not significantly different between WT and M3R−/− mice with CAIA. In M3R−/− mice, levels
of neutrophil chemoattractant chemokine C-X-C-motif ligand 2 (CXCL2) as well as the pro-inflammatory
cytokine interleukin-6 were already strongly increased in mice with low arthritis score, whereas WT mice only
showed prominent expression of these markers when reaching high arthritis scores. Furthermore, arthritic M3R−/− mice
displayed a stronger degradation of collagen II in the articular cartilage and, most strikingly, histopathological
evaluation revealed more severe bone destruction in arthritic mice with M3R deficiency compared to WT littermates.
Moreover, in M3R−/− mice, gene expression of markers for bone degradation (matrix metalloproteinase 13, cathepsin K
and receptor activator of nuclear factor-κB ligand) was already increased in mice with low arthritis score.
Conclusions: Taken together, the present study shows that while M3R−/− mice were not protected from CAIA, they
had a tendency toward a higher inflammatory response after arthritis induction than WT mice. Further, arthritis-induced
joint destruction was significantly stronger in mice with M3R deficiency, indicating that stimulation of M3R might have
protective effects on arthritis.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease, characterized by synovial inflam-
mation resulting in cartilage destruction and bone erosion
[1]. Current therapies such as classical disease-modifying
antirheumatic drugs (DMARDs) and biologicals (e.g., anti-
tumor necrosis factor alpha (TNF-α) treatment) are not
effective in all patients. Thus, the need for new therapeutic
targets in RA is still high. There is increasing evidence
that the non-neuronal cholinergic system (NNCS) might
play a role in the pathology of RA. We and others
demonstrated that all necessary components for a NNCS
such as acetylcholine (ACh) synthesizing and degrading
enzymes, choline and ACh transporters as well as different
muscarinic and nicotinic ACh receptors, are present in
synovial tissue and cartilage of the human joint [2–4].
In different experimental models of arthritis, nicotine
was shown to have ameliorating anti-inflammatory ef-
fects on arthritis symptoms depending on the mode
and time point of application [5–8]. These effects
were considered to be associated with stimulation of
the alpha 7 nicotinic receptor (α7nAChR) [6]. How-
ever, the effect of α7nAChR on arthritis is controver-
sially discussed, as opposite outcomes were published for
experimentally induced arthritis in α7nAChR-deficient
mice [9, 10] or for application of α7nAChR agonists in
arthritis [6, 11]. The role of muscarinic receptors in
arthritis has not been analyzed to date.
Muscarinic receptors (MRs) belong to the family of G
protein-coupled receptors and can be classified in five
distinct subtypes M1R to M5R. M1R, M3R, and M5R
were shown to couple to G proteins of the Gq/11 family,
while M2R and M4R preferentially signal through the
Gi/0 proteins [12]. Stimulation of muscarinic receptors
was shown to mediate many important physiological func-
tions such as smooth muscle contraction and glandular
secretion. Targeting of MRs is a promising treatment
strategy for different pathologies such as overactive blad-
der, chronic obstructive pulmonary disease and Sjögren’s
syndrome [13]. Further, muscarinic receptors are expressed
on various immune cells [14, 15], and activation of
MRs is considered to have mainly pro-inflammatory
function [16]. Stimulation of M3R was shown to in-
duce the expression of pro-inflammatory cytokines and
chemokines and to subsequently influence the recruit-
ment of neutrophils [17–19]. Interestingly, an upregula-
tion of muscarinic receptor expression was observed on
lymphocytes of patients with RA [20]. Further, activation
of M3R was reported to induce the proliferation of
bronchial fibroblasts [21]. As synovial fibroblasts pro-
liferate strongly during pannus formation in RA, we
sought to analyze whether M3R deficiency could be
beneficial for arthritis, leading to reduced inflamma-
tion and joint destruction.
In the present study we used the model of collagen
antibody-induced arthritis (CAIA) to investigate the
effect of M3R on arthritis development. CAIA is a fast
and highly synchronic model to study the inflammatory
phase of arthritis also in mice with C57BL/6 back-
ground, which are usually less responsive for induction
of experimental arthritis [22]. While clinical signs of
arthritis were not significantly different between the two
genotypes, arthritic M3R-deficient mice showed stronger
joint destructive effects and a tendency toward a higher




Mice deficient for M3R (B6.129S6-CF1-Chrm3tm1Jwe;
M3R−/−) and WT littermates (C57BL/6NTac; WT) were ob-
tained from Prof. Dr. J. Wess (National Institutes of Health,
Bethesda, MD, USA). Mice were housed under pathogen-
free conditions, a 12 h light–dark cycle and received food
and water ad libitum. All experiments were approved by
the local ethics committee (Regierungspräsidium Giessen,
GI20/28 Nr. 52–2013).
Collagen antibody-induced arthritis (CAIA)
CAIA was induced in 12-week-old M3R−/− and WT mice
(n = 10; 6 males and 4 females for each genotype) by an in-
traperitoneal (i.p.) injection of 0.2 mg/g body weight anti-
type II collagen 5-clone monoclonal antibody cocktail
(Chondex, Redmond, WA, USA) on day 0. Control mice
(n = 7; 5 males and 2 females for each genotype) received
phosphate-buffered saline (PBS) instead of the anti-
collagen antibody cocktail. On day 3 all mice recieved an
i.p. injection of 2 µg/g body weight lipopolysaccharide
(LPS; E.coli 0111:B4M; Chondrex). The animals were
scored every day for manifestation of arthritic symptoms
in the paws as published by Irmler et al. [23]. Briefly, for
each paw the swelling in wrist/ankle joints and in the
metacarpophalangeal or metatarsophalangeal joints were
graded independently with a score from 0 to 3 (0 = no red-
ness or swelling; 1 = slight swelling and redness; 2 = strong
swelling and redness; 3 =massive swelling and redness).
The number of affected digits or toes was divided by half
and added to the score of each paw. The mice were fur-
ther scored on a daily basis according to their overall con-
dition. The total condition score included the assessment
of body weight, general condition, spontaneous behavior
and arthritis score (total condition score of 0–4 = no
handicap; 5–9 = low handicap; 10–19 moderate handicap; ≥
20 strong handicap). On day 10 the animals were killed
and samples were taken for analysis. Mice were con-
sidered to be arthritic when they reached a cumula-
tive arthritis score (CAS) ≥ 4. As the number of
female animals that reached the critical cumulative
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arthritis score was very low, only male mice were used for
further investigation. Paws from arthritic animals were
taken for analyses when they reached a single paw arthritis
score (SPAS) ≥ 2.
Real-time reverse transcription polymerase chain reaction
(RT-PCR)
Total RNA was isolated from the paws using the RNA
Lipid Tissue Mini Kit (Qiagen, Hilden, Germany). The
Quantitect kit (Qiagen) was used for removal of DNA
contaminations and subsequent reverse transcription
according to the manufacturer’s protocol. Real-time RT-
PCR analysis was performed using the QuantiFast PCR
Kit (Qiagen) and the I-Cycler IQ5™ detection system
(Bio-Rad, Munich, Germany). The following mouse gene-
specific primers were used for amplification: Il6 (152 base
pairs (bp); NM_031168.1) forward 5′-CCTCTCTGCAA
GAGACTTCCATCGA-3′, reverse 5′-AGCCTCCGACT
TGTGAAGTGGT-3′; Cxcl2 (146 bp; NM_009140.2)
forward 5′-GCGCCCAGACAGAAGTCATAGCC-3′,
reverse 5′-CAGCAGCCCAGGCTCCTCCT-3′; Rankl
(86 bp; NM_011613.3) forward 5′-AAGCCTTTCAGG
GGGCCGTG-3′, reverse 5′-GCCTTCCATCATAGCTG
GAGCTCCT-3′; CtsK (81 bp; NM_007802.3) forward 5′-
CAGAGTGGGAAGGCAGGGTCCC-3′, reverse 5′-ACT
GGCCCTGGTTCTTGACTGGA-3′; Mmp13 (125 bp;
NM_008607.2) forward 5′-AGGACCCAGGAGCCCT
GATGTT-3′, reverse 5′-AGGGTTGGGGTCTTCATC
GCCTG, β-actin (165 bp; NM_007393.3) forward 5′-
TGTTACCAACTGGGACGACA-3′, reverse 5′-GGGG
TGTTGAAGGTCTCAAA-3′.
Standard and melt curves were performed to determine
PCR efficiency and specificity of amplification, respect-
ively. Mean cycle thresholds (CT) values were normalized
to the reference gene β-actin (dCT).
FACS analysis of leukocytes in blood
Blood was collected in heparinized tubes and before
centrifugation, 10 μl of blood sample were taken for
determining the absolute number of leukocytes using
CD45-FITC antibody (BioLegend, Fell, Germany) and
AccuCount particles (Spherotech Inc., Lake Forest, IL,
USA). After centrifugation plasma was taken and the cell
pellet was depleted of erythrocytes by two treatment steps
with 50 ml erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM
KHCO3, 0.1 mM Na2EDTA pH 7.3). After washing with
PBS, cells were incubated for 10 min on ice with FACS buf-
fer (1 % fetal bovine serum in PBS) containing 1 μg of puri-
fied anti-mouse CD16/CD32 Fc block (eBioscience,
Frankfurt am Main, Germany) per 106 cells. Cells were sub-
sequently stained for 30 min at 4 °C in the dark with
CD45-APC-Cy7, GR1-BV510 and Ly6C-PerCP-Cy5.5 (all
from BioLegend) and then fixed for 10 min at room
temperature with 1 % paraformaldehyde (PFA; Merck,
Darmstadt, Germany) in PBS. Samples were analyzed
using FACS Canto II flow cytometer and FACS Diva
software (BD Bioscience, Heidelberg, Germany).
Enzyme-linked immunosorbent assay (ELISA)
Interleukin-6 (IL-6) concentration in plasma and paw
homogenates was measured using mouse-specific ELISA
kit (R&D Systems, Wiesbaden, Germany). Paws were lysed
in 20 mM Tris/HCl pH 8.0 containing 137 mM NaCl,
5 mM EDTA, 10 % glycerol, 1 % Triton-X 100, 1 mM
dithiothreitol and 1 mM PMSF. For tissue ELISA, IL-6
concentration was normalized to total protein content of
the paw homogenate, which was determined using the DC
protein assay (Bio-Rad) according to the manufacturer’s
protocol.
Acetylcholine measurement
Samples were prepared for acetylcholine measurement
as published by Klein et al. [24, 25]. Briefly, paws were
homogenized for 5 × 20 s in ice-cold methanol/chloro-
form (2:1; 3 vol/g wet weight) followed by an addition of
1 vol H20 and chloroform and subsequent homogenization.
Hydrophilic phase and lipophilic phase were separated by
centrifugation [25]. The upper hydrophilic phase was
dried by vacuum centrifugation, dissolved in HPLC buffer
(50 mM KHCO3, 1.6 mM sodium decanesulfonate and
0.17 mM EDTA pH 8.3) and then subjected to HPLC
measurement using an Eicom HTEC-500 microbore sys-
tem coupled to a Shimadzu SIL-20 AC autosampler [26].
The detection of the system was 1–2 fmol.
Histological analysis
Knee joints were fixed in 4 % phosphate-buffered PFA
and demineralized in 0.281 M Tris-buffer containing
10 % EDTA (Merck). Sections were cut into a thickness
of 3 μm, deparaffinized, rehydrated, and routinely stained
with hematoxylin and eosin (H&E), alcian blue/PAS
(periodic acid-Schiff ), toluidine blue staining or were
used for enzyme- or immunohistochemistry. Deter-
mination of osteoclasts was performed using enzyme
histochemistry for tartrate-resistant acidic phosphatase
(TRAP). Sections were pretreated with sodium acetate
buffer (pH 5.2) for 10 min and subsequently incu-
bated for 45 min at 37 °C in a solution containing
Naphtol AS-TR phosphate (Sigma-Aldrich, Taufkirchen,
Germany), N,N-dimethylformamid (Sigma-Aldrich), so-
dium tartrate (Merck) and Fast Red TR Salt (Sigma-
Aldrich). Sections were counterstained with hematoxylin
(Shandon Scientific Ltd, Runcorn, UK) and coverslipped
with Kaiser’s glycerol gelatin (Merck).
Collagen II, alpha-smooth muscle actin (α-SMA), neu-
trophils, matrix metalloproteinase 13 (MMP13), cathepsin
K and receptor activator of nuclear factor-κB ligand
(RANKL) were stained using immunohistochemistry. For
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RANKL staining slides were subjected to heat-induced
antigen retrieval with citric buffer (pH 6.0) for 1 h at 60 °C
prior to further treatment. All sections were treated with
3 % H202 to block endogenous peroxidase followed by in-
cubation with 0.2 % hyaluronidase (Biologo, Kronshagen,
Germany) for collagen II or incubation with 1 % bovine
serum albumin (BSA)/PBS for neutrophil staining. Slides
were then subjected to overnight incubation at 4 °C
with the following primary antibodies: rabbit anti-α-
SMA (1:100; Acris, Hiddenhausen, Germany), polyclonal
rabbit anti-collagen II (1:300; Biologo), rat anti-neutrophil
(1:100; NIMP-R14, Abcam, Cambridge, MA, USA), rabbit
anti-MMP13 (1:50, Abcam), goat anti-cathepsin K (1:250,
Santa Cruz Biotechnology, Inc., Heidelberg, Germany)
and rabbit anti-RANKL (1:500, GeneTex, Irvine, CA,
USA). Further, sections were subjected for 45 min to
biotinylated goat anti-rabbit (1:500; Vector Laboratories,
Burlingame, CA, USA), biotinylated rabbit anti-rat (1:150;
Dako, Hamburg, Germany) or biotinylated rabbit anti-
goat antibody (1:800, Dako) and subsequently treated
with Vectastain ABC Elite Kit (Vector Laboratories)
for 30 min at room temperature according to the
manufacturer’s protocol. Staining was visualized using
Nova Red (Vector Laboratories), counterstained with
hematoxylin and DePex (Serva, Heidelberg, Germany)
was used for coverslipping.
Sections were evaluated with a photomicroscope (Axio-
phot 2; Zeiss, Jena, Germany) equipped with a digital
camera (DC500; Leica, Bensheim, Germany). For his-
topathological evaluation of arthritis severity, sections
were scored in a blinded manner regarding changes
in the synovial membrane, cartilage degradation, bone
erosions and synovial blood vessels (Table 1). For quantifi-
cation of neutrophils, the number of immunopositive cells
was counted per high-power field (magnification: 400×).
Transmission electron microscopy (TEM)
Knee joints were fixed in yellow fix (2 % PFA, 2 %
glutaraldehyde and 0.02 % picric acid), washed with
0.1 M cacodylate buffer (pH 7.2) and subsequently
fixed with 1 % osmium tetroxide (OsO4; Fluka, Buchs,
Switzerland). Specimens were dehydrated and embedded
in Epon (Serva, Heidelberg, Germany). Ultra-thin sections
(70–80 nm) were cut, contrasted with uranyl acetate and
lead citrate (Reichert Ultrastainer, Leica, Germany) and
analyzed using a Zeiss EM 912 transmission electron
microscope (Zeiss, Oberkochen, Germany) with a digital
camera (2 K, TRS; Albert Troendle Prototypentwicklung,
Moorenweis, Germany).
Statistical analysis
For statistical analysis the nonparametric Kruskal–Wallis
test was performed followed by the Mann–Whitney U
test. A P value < 0.05 was considered significant. Analyses
were performed using GraphPad Prism software (version
6.0; GraphPad Software Inc., La Jolla, CA, USA).
Results
Clinical data
CAIA was induced in male and female WT and M3R-
deficient mice. In general male mice developed stronger
arthritic symptoms (Fig. 1a) and had a higher incidence
of arthritis development (cumulative arthritis score ≥ 4)
compared to female mice treated the same (Fig. 1b).
There was, however, no significant difference in the
clinical arthritis score between WT and M3R−/− mice for
either sex (Fig. 1a). Interestingly, on day 6 of the experi-
ment, M3R-deficient mice showed a higher incidence of
arthritis (male: 66 % for M3R−/− vs. 50 % for WT;
female: 20 % for M3R−/− vs. 0 % WT mice) and also at
the end of experiment, disease was induced in 80 % of
male M3R−/− mice, while only 66 % of male WT mice
developed arthritic symptoms (Fig. 1b). As only 20 % of
female mice developed arthritic symptoms, we decided
to continue the study using only male mice. Generally,
the overall physical condition of male M3R−/− mice
seemed to be more affected by CAIA induction. Especially
on day 4, one day after LPS injection, the total body condi-
tion score was significantly enhanced in M3R-deficient
compared to WT mice (Fig. 1c). This was further reflected
by the weight loss observed for M3R-deficient mice, as
over the whole experiment the average body weight of
arthritic M3R−/− mice was significantly reduced compared
to WT mice with arthritis (Fig. 1d). Acetylcholine was
Table 1 Histological score for evaluation of pathological changes in synovial membrane, cartilage, bone and blood vessels
Score Synovial membrane Cartilage Bone -SMA
0 No changes No changes No changes Few blood vessels, none with
thickened walls
1 >2 cell layers, moderate immune
cell infiltration
Erosion in parts of cartilage
surface
Bone remodeling only close to
the joint capsule
Few blood vessels, few with thickened
walls
2 >5 cell layers, strong immune cell
infiltration, starting pannus formation
Erosion of cartilage surface,
cartilage destruction
Bone remodeling also in deeper
parts reaching epiphyseal plate
Increased number of blood vessels,
some of them with thickened walls
3 Like score 2 + pannus formation +
more blood vessels
Like score 2 + cartilage
covered by connective tissue
Like score 2 + bone degradation Many blood vessels, most of them
(more than 50 %) with thickened walls
α-SMA alpha-smooth muscle actin
Beckmann et al. Arthritis Research & Therapy  (2016) 18:17 Page 4 of 16
detectable in paws of all animals in a range between 19.2
and 288.3 pmol/g wet weight (97.24 ± 18.66, mean ± SEM,
n = 20). However, due to large variations between samples,
there were no significant differences between individual
groups.
Histopathological changes in synovial membrane
Histological analysis of knee joints revealed classical syn-
ovial changes in arthritic WT and M3R-deficient mice
compared to nonarthritic LPS controls (Fig. 2). While
there was only a thin layer of synovial cells in LPS con-
trol animals, arthritic mice displayed a strong thickening
and pannus formation of synovial membrane. Interest-
ingly, the synovial tissue of arthritic M3R-deficent mice
seemed to show a tendency toward more severe patho-
logical changes, which were, however, not statistically sig-
nificant when compared to arthritic WT mice (Fig. 2h).
Ultrastructural analysis of synovial macrophages and fi-
broblasts clearly showed hypertrophy of both cell types in
arthritic animals (Fig. 2i–p). In mice with CAIA a higher
Fig. 1 Mice deficient for M3R were not protected from clinical signs of arthritis. a Clinical arthritis score for WT and M3R−/− mice with CAIA. Male
(n = 6 for each genotype) and female (n = 4 for each genotype) mice of the respective CAIA group were taken for analysis. The cumulative
arthritis score (CAS) on each day of experiment is represented as mean ± SEM. b Incidence of arthritis development in male (n = 6 for each
genotype) and female (n = 4 for each genotype) WT and M3R−/− mice with CAIA. Incidence is given as percentage of mice per group that
reached a CAS 4 on the indicated day of experiment. c Total physical condition score of male LPS control (n = 5 for each genotype) and
arthritic (CAS 4) WT (n = 4) and M3R-deficient (n = 5) mice. The total condition score for every day of experiment is given as mean ± SEM.
Asterisks indicate statistical significance (*P < 0.05: CAIA vs. respective LPS control; #P < 0.01: M3R−/−-CAIA vs. WT-CAIA). d Average body weight
of male LPS control and arthritic M3R−/− and WT mice. For each group the average percentage of body weight throughout the experiment
compared to experimental day 0 is given as mean ± SEM. *P < 0.05: CAIA vs. respective LPS control; #P < 0.05: M3R−/−-CAIA vs. WT-CAIA. CAIA
collagen antibody-induced arthritis, LPS lipopolysaccharide, M3R M3 muscarinic acetylcholine receptor, WT wild-type
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Fig. 2 Synovial changes in WT and M3R-deficient mice with CAIA. a–g Hematoxylin and eosin (H&E) staining of knee joint sections from male
WT-LPS (a), M3R−/−-LPS (b, e), WT-CAIA (c, f) and M3R−/−-CAIA (d, g) mice. Original magnification: 25× (a–d) and 200× (e–g). h Quantification of
histopathological changes in knee joint synovial tissue of male arthritic WT and M3R−/− mice. Data are given as mean histopathological score ±
SEM. i–p Transmission electron microscopy of synovial macrophages (i–l) and fibroblasts (m–n) of male WT-LPS (i and m), M3R−/−-LPS (j and n),
WT-CAIA (k and o) and M3R−/−-CAIA (l and p) mice. Original magnification: 5000×. CAIA collagen antibody-induced arthritis, LPS lipopolysaccharide,
M3R M3 muscarinic acetylcholine receptor, WT wild-type
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number of vacuoles and endoplasmatic reticulum was
observed in synovial macrophages and fibroblasts,
respectively.
One characteristic feature of arthritis is an increase in
the amount of blood vessels in the diseased synovial
tissue. Thus, we performed immunohistochemistry for
α-SMA, labeling vascular smooth muscle cells (Fig. 3).
The staining and respective histopathological scoring
(Fig. 3h) revealed a significantly enhanced number of
α-SMA-positive blood vessels including vessels with
thickened walls in M3R−/−-CAIA mice when compared to
respective LPS control mice. Interestingly, compared to
M3R−/−-LPS mice, WT-LPS control mice showed a higher
histopathological score, which was not markedly enhanced
by CAIA induction (Fig. 3e and h).
Inflammatory response
Induction of arthritis led to a substantial increase of
total leukocyte number in the blood of M3R-deficient,
but not of WT mice (Fig. 4a). Further, the number of
circulating neutrophils was not significantly changed by
arthritis induction in WT mice (Fig. 4b). Interestingly, in
the blood of M3R-deficient LPS control mice, neutrophil
count was markedly increased compared to WT mice.
Induction of arthritis led to a further, modest, but not
statistically significant enhancement of circulating neu-
trophils in M3R-deficient mice (Fig. 4b). Immunohisto-
chemistry for neutrophils demonstrated that arthritis
induction resulted in a strong infiltration of neutrophils
in the knee joint of arthritic animals (Fig. 4c–g). Quanti-
fication of immunopositive cells revealed higher numbers
of neutrophils in knee joints of arthritic M3R-deficient
mice when compared to WT-CAIA mice. However, this
difference was not statistically significant, due to a large
variation between samples (Fig. 4g). We further found that
mRNA expression of chemokine (C-X-C motif) ligand 2
(CXCL2), a main chemoattractant for neutrophils, was
strongly upregulated in paws of arthritic mice (Fig. 4h).
Correlating the expression of Cxcl2 with the arthritis
scores of the respective paws revealed that Cxcl2 expres-
sion in paws of arthritic M3R-deficient mice was already
markedly enhanced in paws with low arthritis score
Fig. 3 Analysis of -SMA positive blood vessels in arthritic and nonarthritic WT and M3R−/− mice. a–g Immunohistochemical staining for -SMA
in knee joints of male WT-LPS (a, e), M3R−/−-LPS (b, f), WT-CAIA (c) and M3R−/−-CAIA (d, g) mice. Original magnification: 200× (a–d) and 1000×
(e–g). h Histopathological score for -SMA staining. Data are given as mean histopathological score ± SEM. *P < 0.05 CAIA vs. respective LPS
control. CAIA collagen antibody-induced arthritis, LPS lipopolysaccharide, M3R M3 muscarinic acetylcholine receptor, WT wild-type, α-SMA
alpha-smooth muscle actin
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(Fig. 4i). In WT mice, however, strong induction of Cxcl2
expression was only observed in paws with higher arthritis
score (Fig. 4i).
ELISA measurement of circulating pro-inflammatory
cytokine interleukin (IL)-6 revealed a modest, but not
statistically significant, increase in plasma of arthritic
mice (Fig. 5a). Interestingly, in mice deficient for M3R,
abundance of circulating IL-6 was strongly enhanced in
mice with low cumulative arthritis score (CAS), while
WT mice only showed high plasma IL-6 levels when
they reached a high CAS (Fig. 5b). Thus, the ratio of
plasma IL-6 concentration to CAS was significantly
Fig. 4 Higher number of pro-inflammatory cells in circulation and joints of M3R-deficient mice. a, b Quantification of FACS analysis of total
CD45+ (a) and CD45 + Ly6C + GR1+ (b) cells in whole blood from male LPS control and arthritic M3R−/− and WT animals. Data are given as
box plots with the median indicated by a solid line within the box. *P < 0.05 CAIA vs. respective LPS control; #P < 0.05: M3R−/−-CAIA vs. WT-CAIA;
§P < 0.05: M3R−/−-LPS vs. WT-LPS. c–f Immunohistochemical staining for neutrophils in knee joints of male WT-LPS (c), M3R−/−-LPS (d), WT-CAIA (e),
M3R−/−-CAIA (f) mice. Original magnification: 200×. g Quantification of neutrophil staining with data given as average number of positive cells per
high-power field (hpf) ± SEM. *P < 0.05 CAIA vs. respective LPS control. h Real-time RT-PCR analysis of Cxcl2 mRNA expression in paws of male WT and
M3R−/− mice with CAIA and respective LPS-treated control mice, normalized to β-actin mRNA. Data are given as –dCT values presented as box plots.
*P < 0.05 and **P< 0.01 CAIA vs. respective LPS control. i Correlation of Cxcl2 mRNA expression with the arthritis score of the respective paw in arthritic
WT and M3R−/− mice. Dotted lines indicate the mean Cxcl2 mRNA expression of the corresponding LPS-treated control mice. CAIA collagen antibody-
induced arthritis, LPS lipopolysaccharide, M3R M3 muscarinic acetylcholine receptor, WT wild-type
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higher in M3R-deficient mice compared to WT mice
(Fig. 5c). Further, IL-6 mRNA expression was markedly
increased in paws of arthritic animals, however, only
in paws of M3R-deficient animals was the increase
statistically significant (Fig. 5d). ELISA measurements
in paw homogenates showed that IL-6 protein was
significantly increased in arthritic paws of both WT
and M3R-deficient mice, with a tendency toward stronger
induction in M3R−/−-CAIA mice (Fig. 5e).
Joint destruction
Articular cartilage in knee joints of nonarthritic LPS
control animals had a smooth surface (Fig. 6a–b and e),
while in arthritic animals the surface was rough and
destroyed at many places (Fig. 6c–d and f–g). There
was, however, no obvious difference in cartilage destruc-
tion between arthritic WT and M3R-deficient mice. We
further stained the knee joint sections for collagen II,
the main constituent of articular cartilage. Full staining
of cartilage was observed in both LPS control groups
(Fig. 6i–j) while in arthritic mice parts of cartilage did
not show immunoreactivity for collagen II (Fig. 6k–l).
This loss of collagen II seemed to be enhanced in
M3R−/−-CAIA mice when compared to WT-CAIA
mice. Taking a closer look at the ultrastructure of
chondrocytes (Fig. 6m–p) revealed that, compared to
cells of LPS controls and WT-CAIA mice, chondro-
cytes of arthritic M3R-deficient mice looked less vital,
with dense chromatin and cytoplasmic vacuoles (Fig. 6p).
Further, toluidine blue-stained sections of knee joints
were evaluated regarding the degree of bone destruction
(Fig. 7a–d). Remarkably, histopathological quantification
of arthritis-induced changes in bone structure revealed
that bone erosion was significantly enhanced in arthritic
M3R-deficient mice compared to WT mice with CAIA
(Fig. 7e). The process of bone degradation seemed to
involve osteoclasts, as TRAP-positive multinucleated
cells were detected in areas of erosive bone (Fig. 7f–h).
While osteocytes of both WT and M3R−/− nonarthritic
LPS control animals had normal ultrastructure (Fig. 7i
and j), transmission electron microscopy showed that
osteocytes in arthritic WT animals had a slightly swollen
appearance with little pericellular space around the
cytoplasm (Fig. 7k). The same was observed for osteocytes
of arthritic M3R-deficient mice, however, here mainly
osteocytes with shrinkage of cytoplasm and expanded
pericellular space were observed in M3R−/−-CAIA mice
(Fig. 7l). These osteocytes showed many cytoplasmatic
processes, the pericellular space appeared brighter and
cells looked generally less vital.
Fig. 5 Effect of M3R-deficiency on pro-inflammatory cytokine IL-6 in mice with CAIA. a Enzyme-linked immunosorbent assay (ELISA) measurement
of IL-6 concentration in plasma of male arthritic WT and M3R−/− mice and respective LPS-treated control mice. b Correlation of circulating IL-6
abundance with the respective cumulative arthritis score (CAS) of arthritic WT and M3R−/− mice. Dotted lines indicate the mean IL-6 concentration
of the respective LPS-treated control mice. c Ratio of plasma IL-6 level and CAS in arthritic male WT and M3R−/− mice given as mean ± SEM.
#P < 0.05: M3R−/−-CAIA vs. WT-CAIA. d Real-time reverse transcription polymerase chain reaction (RT-PCR) analysis of Il6 mRNA expression in paws
of male WT and M3R−/− mice with CAIA and respective LPS-treated control mice, normalized to β-actin mRNA. **P < 0.01 CAIA vs. respective
LPS control. e ELISA measurement of IL-6 concentration in paw homogenates of male LPS-treated and arthritic WT and M3R−/− mice. Data
were normalized to total protein concentration. *P < 0.05 and **P < 0.01 CAIA vs. respective LPS control. CAIA collagen antibody-induced arthritis,
CAS cumulative arthritis score, IL-6 interleukin-6, LPS lipopolysaccharide, M3R M3 muscarinic acetylcholine receptor, WT wild-type
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Fig. 6 Analysis of cartilage destruction in arthritic WT and M3R−/− mice. a–g Alcian blue/periodic acid-Schiff (PAS) staining on knee joint sections
from male WT-LPS (a, e), M3R−/−-LPS (b), WT-CAIA (c, f), and M3R−/−-CAIA (d, g) mice. Original magnification: 100× (a–d) and 1000× (e–g). Arrows
indicate regions of interest. h Histopathological quantification of cartilage destruction in knee joints of male arthritic WT and M3R−/− mice. Data
are given as mean of histopathological score ± SEM. i–l Immunohistochemical staining for collagen II (original magnification 200×) in sections
from knee joints of male WT-LPS (i), M3R−/−-LPS (j), WT-CAIA (k) and M3R−/−-CAIA (l) mice. m–p Transmission electron microscopy of chondrocytes in
knee joints of male WT-LPS (m), M3R−/−-LPS (n), WT-CAIA (o) and M3R−/−-CAIA (p) mice. Original magnification: 5000×. CAIA collagen antibody-induced
arthritis, LPS lipopolysaccharide, M3R M3 muscarinic acetylcholine receptor, WT wild-type
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Expression of genes involved in bone destruction,
namely matrix metalloproteinase 13 (MMP13), receptor
activator of nuclear factor-κB ligand (RANKL) and ca-
thepsin K (CtsK) was further analyzed in paws of control
and arthritic M3R−/− and WT animals by real-time
RT-PCR and immunohistochemistry (Fig. 8). Mmp13
mRNA expression in paws was markedly enhanced by
arthritis induction in both WT and M3R-deficient
mice. Interestingly, in M3R-deficient mice, mRNA ex-
pression of Mmp13 was already prominently induced
in paws with low arthritis scores while in WT animals
only paws with an arthritis score > 4 showed high levels of
Mmp13 (Fig. 8b). Immunohistochemical staining in the
knee joints showed that MMP13 protein was localized
mainly in the chondrocytes of the articular cartilage.
However, using this method, we were not able to find clear
differences between LPS control and arthritic mice (exem-
plarily shown for M3R-deficient mice in Fig. 8c–d). Rankl
mRNA expression was significantly enhanced by arthritis
induction in both WT and M3R-deficient mice (Fig. 8e),
Fig. 7 Stronger effect of CAIA on bone destruction in M3R-deficient mice. a–d Toluidine blue staining on sections from knee joints of male WT-LPS (a),
M3R−/−-LPS (b), WT-CAIA (c), and M3R−/−-CAIA (d) mice. Original magnification: 200×. e Histopathological quantification of bone destruction in
knee joints of male arthritic WT and M3R−/− mice. Data are given as mean of histopathological score ± SEM. #P < 0.05: M3R−/−-CAIA vs. WT-CAIA.
f–h Toluidine blue staining (f) and immunohistochemistry for tartrate-resistant acidic phosphatase (TRAP) (g and h) on section from knee joint of
representative male M3R−/−-CAIA mouse. Original magnification: 200× (f, g) and 1000× (h) The square in g indicates the area shown in h.
i–l Transmission electron microscopy of osteocytes in knee joints of male WT-LPS (i), M3R−/−-LPS (j), WT-CAIA (k) and M3R−/−-CAIA (l)
mice. Original magnification: 6300×. CAIA collagen antibody-induced arthritis, LPS lipopolysaccharide, M3R M3 muscarinic acetylcholine receptor,
WT wild-type
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but same as for Mmp13 mRNA, M3R-deficient mice
reached higher expression levels of Rankl already in paws
with low arthritis score (Fig. 8f). Immunohistochemistry
for RANKL protein revealed its localization primarily in
synoviocytes (Fig. 8g–h) and chondrocytes of the knee
joint, showing a higher abundance in arthritic mice when
compared to LPS control mice, confirming the mRNA
data. Ctsk mRNA expression was significantly induced
only in arthritic M3R-deficient mice (Fig. 8i) and also
here, the expression was comparably high already in
paws with low arthritis scores (Fig. 8j). Cathepsin K pro-
tein was localized immunohistochemically in synoviocytes
Fig. 8 Analysis of markers for joint destruction in arthritic WT and M3R−/− mice. Real-time reverse transcription polymerase chain reaction (RT-PCR)
analysis of Mmp13 (a), Rankl (e), and Ctsk (i) mRNA expression in paws of male WT and M3R−/− mice with CAIA and respective LPS-treated control mice,
normalized to β- actin mRNA. *P < 0.05 and **P < 0.01 CAIA vs. respective LPS control. Correlation of Mmp13 (b), Rankl (f) and Ctsk (j) mRNA
expression with the arthritis score of the respective paw in male arthritic WT and M3R−/− mice. Dotted lines indicate the mean mRNA expression of
the respective LPS-treated control mice. Immunohistochemical staining for matrix metalloproteinase 13 (MMP13) (c–d), receptor activator of nuclear
factor-κB ligand (RANKL) (g–h) and cathepsin K (k–l) in knee joint sections from male M3R−/−-LPS (c, g and k) and M3R−/−-CAIA (d, h and l) mice.
Original magnification: 100× (c–d) and 400× (g–h and k–l). CAIA collagen antibody-induced arthritis, Ctsk cathepsin K, LPS lipopolysaccharide, M3R
M3 muscarinic acetylcholine receptor, Mmp13 matrix metalloproteinase 13, Rankl receptor activator of nuclear factor-κB ligand, WT wild-type
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(Fig. 8k–l) as well as chondrocytes and showed a higher
abundance in arthritic mice when compared to LPS
control mice.
Discussion
In the present study we first found that M3R-deficient
mice responded to collagen antibody-induced arthritis
similarly to WT mice. Upon further characterization,
however, M3R−/− mice displayed a tendency toward a
higher inflammatory response than WT mice. Further-
more, arthritis-induced joint destruction was significantly
stronger in mice with M3R deficiency.
No difference in clinical arthritis scores was observed
between WT and M3R-deficient mice, but M3R defi-
ciency led to a slightly higher incidence of disease induc-
tion. According to previous studies, no sex differences
occur in C57BL/6 mice when using LPS boost injection
to induce arthritis [27, 28]. When CAIA was induced in
both male and female mice of each genotype, however,
we clearly observed differences in arthritis development
between male and female mice. Contrary to the human
situation where incidence of RA is higher in female pa-
tients, male mice were affected more strongly by CAIA
induction than female mice. Such sex-specific effect is
known, e.g., for the model of collagen-induced arthritis
[29]. Even though the incidence of arthritis was slightly
increased in M3R-deficient mice, there were no obvious
differences in clinical arthritis score compared to WT
mice. As only a small number of female mice developed
arthritic symptoms, we further conducted this study
using only male mice. The overall physical condition of
M3R-deficient mice was more affected by disease in-
duction. Moreover, M3R−/− mice with CAIA showed a
significantly stronger reduction in body weight over
the whole experiment than WT mice. In general, mice
deficient for M3R are known to have a hypophagic and
lean phenotype, due to a lack of the central cholinergic
effect on food intake and an increase in energy expend-
iture [30, 31]. This phenotype might be more pronounced
when mice are challenged.
Cholinergic control of inflammation is a widely dis-
cussed topic and, especially since the “cholinergic anti-
inflammatory pathway” was identified by the group of
Tracey and coworkers [32–34], the anti-inflammatory
role of the α7nAChR was extensively analyzed. Less
research was focused on the role of muscarinic recep-
tors, which were reported to have a pro-inflammatory
function [16]. In the present study, however, M3R-
deficient mice showed a stronger inflammatory response
after arthritis induction than WT mice. Expression of the
pro-inflammatory cytokine IL-6 and the number of infil-
trating neutrophils was markedly increased in arthritic
joints of both genotypes, but infiltration of neutrophils
was slightly stronger in M3R-deficient mice. Neutrophils
are key players in the pathology of CAIA, and depletion of
these cells was shown to have a strong beneficial effect
[28]. In accordance with the profound neutrophil infiltra-
tion in the arthritic joint, we could further demonstrate
that mRNA expression of CXCL2, a main chemoattractant
for neutrophils, was significantly induced in whole joints
of arthritic WT and M3R-deficient mice. Interestingly, in
M3R-deficient mice Cxcl2 expression was already mark-
edly enhanced in paws with low arthritis score, while in
WT mice only strongly arthritic paws revealed high ex-
pression of this chemokine.
This stronger inflammatory response in mice lacking
M3R was surprising, as opposite findings were reported
for, e.g., chronic obstructive pulmonary disease (COPD)
or LPS-induced endotoxemia, where muscarinic recep-
tor antagonists had anti-inflammatory effects [35, 36].
The total number of circulating leukocytes and, more
specifically, of circulating neutrophils was significantly
enhanced in the blood of arthritic M3R-deficient mice,
but not of WT mice. Surprisingly, in our study, LPS-
injected M3R-deficient mice had significantly higher
numbers of circulating neutrophils than LPS-treated
WT mice. This finding indicates that LPS application
without induction of arthritis had a stronger systemic
pro-inflammatory effect when M3R was absent. For WT
animals a significant increase in immune cells was only
observed directly in the affected joint, but not systemic-
ally in the blood. The dose of antibody and LPS used to
induce arthritis may not have been strong enough to
promote a systemic response in WT mice. Alternatively,
the systemic inflammatory response may already have been
reduced to non-detectable levels at day 10 of experiment,
whereas in M3R-deficient mice it remained elevated. The
same might be true for the pro-inflammatory cytokine
IL-6, which was not significantly elevated in the circula-
tion of arthritic mice at day 10. However, M3R−/−-CAIA
mice again displayed higher levels of IL-6 than WT mice.
One explanation for the observed pro-inflammatory
effects in M3R−/− mice could be the lack of central
cholinergic activation of M3 receptors as anti-inflammatory
effects were reported for centrally acting muscarinic
agonists [37, 38].
Synovial tissue showed typical pathology in all arthritic
mice, with a tendency toward more pronounced patho-
logical changes in M3R−/−-CAIA mice. Pannus-forming
synovial tissue is highly vascularized and thickening of
blood vessel walls can be observed under arthritic condi-
tions [39]. Many components of the NNCS including the
acetylcholine-synthesizing enzyme choline acetyltransfer-
ase (ChAT) were reported to be present in the vasculature
[40, 41]. Furthermore, nicotine acts as a pro-angiogenic,
mainly via α7nAChR, and may be involved in the path-
ology of atherosclerosis [42, 43]. Activation of M3R in the
vasculature can have different functions, depending on the
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cell type. While M3R on endothelial cells causes vasodila-
tation, M3R on vascular smooth muscle cells can cause
vasoconstriction [44]. In our study, the number of α-
SMA-positive blood vessels was significantly increased by
CAIA induction in M3R-deficient mice. Interestingly, the
α-SMA histopathological score was strongly enhanced in
nonarthritic WT-LPS control mice when compared to
M3R−/−-LPS mice. Kistemaker and colleagues hypothe-
sized that M3R is involved in smooth muscle mass devel-
opment, mainly because they found that M3R-deficient
mice have lower basal levels of α-SMA in airway arteries
and bronchial tissue [45]. This is in accordance with the
findings in our study, and this low basal level of α-SMA
was strongly induced by CAIA, while for WT mice such
induction by arthritis was not observed.
Histopathological scoring of cartilage erosion, mainly
regarding surface regularity, did not reveal significant
differences between WT and M3R−/− mice with CAIA.
Collagen II is the major constituent of articular and
hyaline cartilage, but when this cartilage is destroyed,
fibrocartilage is formed. Fibrocartilage mainly contains
collagen I and is more dense and less elastic than hyaline
cartilage. Thus, when specifically collagen II was marked
using immunohistochemistry, arthritic M3R-deficient
mice seemed to show enhanced loss of collagen II in the
articular cartilage, when compared to WT mice with
CAIA. Loss of collagen II in rheumatoid arthritis is asso-
ciated with an increase in matrix-degrading enzymes
(e.g., MMP13) [46] and a decrease in collagen II synthesis
[47]. In previous work, activation of muscarinic receptors
induced collagen synthesis in human lung fibroblasts and
M3R-deficient mice displayed reduced collagen deposition
in allergen-induced airway remodeling [45, 48]. Thus, the
enhanced loss of collagen II in M3R−/− mice could be
partly due to an impairment of collagen synthesis when
mice are subjected to CAIA induction. Moreover, in
arthritic M3R−/− mice, mRNA expression of MMP13 was
already strongly enhanced in paws with low arthritis score,
when compared to WT mice with CAIA, indicating
that collagen II degradation might be stronger in M3R-
deficient mice. MMP13 protein was mainly expressed by
chondrocytes of the knee joint, however, we could not
make out clear differences in MMP13 abundance between
LPS control and arthritic animals using immunohisto-
chemistry. However, it could be that the amount of
MMP13 protein expressed per cell might be increased,
but the number of MMP13-expressing cells per se re-
mains the same under pathological conditions.
MMP13 is not only an important factor for cartilage
degradation in arthritis, but additionally plays an essen-
tial role for the inflammatory response and bone degrad-
ation [49, 50]. Accordingly, the histopathological score
evaluating bone degradation was significantly enhanced
in arthritic M3R−/− mice compared to WT mice with
CAIA. Interestingly, osteocytes of arthritic M3R-deficient
animals seemed less vital. Not long ago, osteocytes were
considered to be functionless, quiescent cells. However, in
recent years it became obvious that these cells have many
important functions such as mineralization, formation
and resorption of bone as well as sensing of mechanical
load [51] and these important pathways might be affected
in arthritic M3R-deficient mice.
Generally, bone structure is known to be positively
affected by activation of M3R, since M3R-deficient mice
were shown to have an osteoporosis-like phenotype
[52, 53] and M3R was found to be upregulated in
osteoporotic rats [54]. Thus, the stronger bone destruction
in M3R−/− mice might not be a surprise. On the other
hand, Shi et al. reported that the M3R-mediated effect on
bone mass is dependent on the sympathetic tone and the
β2 adrenergic receptor [52]. The sympathetic nervous
system acts as negative regulator of bone mass accrual via
the β2 adrenergic receptor on osteoblasts, and activation
of M3R evidently dampens the sympathetic tone, leading
to an increase in bone mass [52]. It is known that the
sympathetic innervation as well as the β2 adrenergic re-
ceptor expression is reduced during the course of arthritis
[55–57]. Therefore, the effect of M3R on bone mass via
this pathway could be reduced as well and might be less
relevant in this setting.
Additionally to MMP13, mRNA expression of cathep-
sin K and RANKL was already strongly increased in
M3R-deficient paws with low arthritis score, while in
WT animals enhanced expression was only observed in
paws with high arthritis score. Immunohistochemically,
we confirmed enhanced protein abundance of both ca-
thepsin K and RANKL in synoviocytes and chondroyctes
of the arthritic knee joint. Cathepsin K is a cysteine
protease which is expressed predominantly by osteo-
clasts but also by synoviocytes. It plays an important
part in bone as well as cartilage degradation and its
expression can be upregulated by pro-inflammatory
cytokines [58, 59]. RANKL is a key mediator of osteo-
clast formation and is expressed by many different cell
types including osteocytes [60]. RANKL expressed on
synovial fibroblasts seems to be primarily responsible for
bone erosions during inflammatory arthritis [61]. How-
ever, neutrophils were also identified as potent mediators
of bone erosions in RA, as these cells were shown to
express RANKL [62, 63]. Thus, the enhancement of joint
destruction in arthritic M3R-deficient mice could also be
partly due to the stronger inflammatory response shown
in these mice.
Transferring these observations to the clinical situation,
one might speculate that treatment of patients with
M3R agonists might possibly have protective effects
for RA. Due to a high similarity between the different
receptor subtypes, therapeutic targeting of specific
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muscarinic receptors is challenging. However, recent
advances in the development of subtype-specific allo-
steric agonists and antagonists may pave the way for
a successful targeting of M3R [13].
Conclusions
In this manuscript, we investigated the role of M3R in
experimentally induced arthritis. Arthritic M3R−/− mice
showed stronger bone destruction, enhanced collagen II
loss in articular cartilage and a tendency toward a stronger
inflammatory response, even though clinical arthritis
score was not changed as compared to arthritic WT
mice. Thus, stimulation of M3R might have protective
effects on arthritis.
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